On August 8, 2023, Bavarian Nordic announced positive top-line results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of its Chikungunya virus candidate vaccine, CHIKV VLP (PXVX0317), in adults and adolescents aged 12 to 64.
The KRAS G12D mutation affects approximately 180,000 patients in the United States and Europe, showing an incidence rate about 2.5 times higher compared to the KRAS G12C mutation.
On August 8, 2023, Vistagen announced the positive top-line results of the PALISADE-2 Phase 3 clinical trial, which assessed the efficacy and safety of its investigational fasedienol (PH94B, Aloradine) nasal spray in adult patients with social anxiety disorder (SAD).
The success of CAR-T in hematologic malignancies lays the foundation for treating solid tumors, and oncology results will provide crucial knowledges for converting CAR-T to other diseases.
the approved dose for BMS's Deucravacitinib treatment of psoriasis is 6mg QD, whereas the estimated dose for TAK279 clinical treatment of psoriasis is over 30mg QD. Why does TAK279 have BIC potential?
As research has progressed, CAR-T’s efficacy has been found to extend beyond cancer with great potential in treating autoimmunity, infections, fibrosis, aging-related diseases and more.
STAT6 is essential for IL-4 and IL-13 signal transduction, but it is downstream of the JAK/STAT pathway and is not utilized by other cytokines and growth factors.